Program
Lidocaine
Also written as “Lidoderm®”, “Lidocaine topical system 1.8%” and “Lidoderm”.
Its studies are mostly in Pain · Neuralgia, Postherpetic · Attention Deficit Disorder with Hyperactivity · Osteoarthritis, Knee · Low Back Pain, led by 25 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keenova Therapeutics | 110 open or running | phase 4since May 15, 2009 | Dec 15, 2005 | none ahead |
| Scilex Pharmaceuticals | 80 open or running | phase 1since Oct 28, 2019 | Oct 28, 2019 | none ahead |
| ZARS Pharma | 60 open or running | phase 4since Sep 3, 2008 | Sep 3, 2008 | none ahead |
| Grünenthal | 40 open or running | phase 3since Sep 12, 2012 | Jul 1, 2010 | none ahead |
| AlgoRx Pharmaceuticals | 30 open or running | phase 3since Aug 31, 2005 | Aug 15, 2005 | none ahead |
| PhenoSolve | 30 open or running | early phase 1since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Astellas Pharma | 10 open or running | phase 4since Aug 11, 2011 | Aug 11, 2011 | none ahead |
| AstraZeneca | 10 open or running | early phase 1since Feb 16, 2011 | Feb 16, 2011 | none ahead |
| cartiva-inc | 10 open or running | phase 2since Feb 17, 2014 | Feb 17, 2014 | none ahead |
| centrexion-therapeutics | 10 open or running | phase 1since Feb 9, 2015 | Feb 9, 2015 | none ahead |
| chemische-fabrik-kreussler-co-gmbh | 10 open or running | phase 4since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Galderma Group | 10 open or running | phase 4since Feb 24, 2012 | Feb 24, 2012 | none ahead |
| Hamad Medical | 10 open or running | phase 3since Sep 10, 2020 | Sep 10, 2020 | none ahead |
| Ipsen | 10 open or running | phase 2since Sep 6, 2018 | Sep 6, 2018 | none ahead |
| isdin | 10 open or running | phase 2since May 24, 2011 | May 24, 2011 | none ahead |
| isifer-ab | 10 open or running | phase 2since Apr 4, 2011 | Apr 4, 2011 | none ahead |
| j-a-r-laboratories | 10 open or running | no phasesince Apr 18, 2016 | Apr 18, 2016 | none ahead |
| juniper-pharmaceuticals-inc | 10 open or running | phase 2since Mar 28, 2008 | Mar 28, 2008 | none ahead |
| Lee's Pharmaceutical | 10 open or running | phase 3since Aug 28, 2018 | Aug 28, 2018 | none ahead |
| lumara-health-inc | 10 open or running | phase 2since Dec 26, 2007 | Dec 26, 2007 | none ahead |
| Mundipharma | 10 open or running | phase 3since May 20, 2015 | May 20, 2015 | none ahead |
| Novartis | 10 open or running | phase 3since Dec 20, 2010 | Dec 20, 2010 | none ahead |
| Orexa BV | 11 open or running | phase 2since Jun 9, 2023 | Jun 9, 2023 | none ahead |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Dec 4, 2012 | Dec 4, 2012 | none ahead |
| scivision-biotech-inc | 10 open or running | no phasesince Dec 4, 2013 | Dec 4, 2013 | none ahead |
Also a collaborator on its studies: prevail-infoworks, qps-holdings-llc, anfomed-gmbh and nuvo-research-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 34 studies since Aug 15, 2005.
- May 20, 2015Mundipharma's first study: phase 3 study in Herpes Zoster PainNew to MundipharmaMundipharma · NCT02452112 · 243 enrolled · China
- Apr 18, 2016j-a-r-laboratories's first study: no phase study in Back PainNew to j-a-r-laboratoriesj-a-r-laboratories · NCT02749123 · 100 enrolled · United States
- Nov 14, 2017chemische-fabrik-kreussler-co-gmbh's first study: phase 4 study in PeriodontitisNew to chemische-fabrik-kreussler-co-gmbhchemische-fabrik-kreussler-co-gmbh · NCT03354312 · 94 enrolled · Germany
- Aug 28, 2018Lee's Pharmaceutical's first study: phase 3 study in Acute PainNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT03653260 · 288 enrolled · China
- Sep 6, 2018Ipsen's first study: phase 2 study in Chronic Scar PainNew to IpsenIpsen · NCT03663101 · 16 enrolled · United Kingdom
- Sep 17, 2018PhenoSolve's first studies: 2 early phase 1 studies in Attention Deficit Disorder with HyperactivityNew to PhenoSolvePhenoSolve · NCT03680885, NCT03676725
- Nov 15, 20182 phase 3 studies in Neuralgia, PostherpeticGrünenthal · NCT03745404, NCT03765697
- Oct 28, 2019Scilex Pharmaceuticals's first studies: 3 phase 1 studies in HealthyNew to Scilex PharmaceuticalsScilex Pharmaceuticals · NCT04144192, NCT04150536, NCT04149938
- Nov 12, 2019Early phase 1 study in Attention Deficit Disorder with HyperactivityPhenoSolve · NCT04167189 · 28 enrolled · United States
- Mar 16, 20203 phase 1 studies in HealthyScilex Pharmaceuticals · NCT04312750, NCT04320173, NCT04319926
- Sep 10, 2020Hamad Medical's first study: phase 3 study in Pain, ProceduralNew to Hamad MedicalHamad Medical · NCT04571879 · 48 enrolled · Qatar
- Mar 3, 2021Phase 1 study in HealthyScilex Pharmaceuticals · NCT04784728 · 24 enrolled · United States
- Oct 11, 2021Phase 1 study in HealthyScilex Pharmaceuticals · NCT05106400 · 24 enrolled · United States
- Jun 9, 2023Orexa BV's first study: phase 2 study in Ileus PostoperativeNew to Orexa BVOrexa BV · NCT05923086 · 126 planned · Germany
TargetBeta
“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 54 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05923086Ileus Postoperative · Germany | 2 | Recruiting | Orexa BV | Dec 31, 2025 | 126 |
| NCT05106400Healthy · United States | 1 | Completed | Scilex Pharmaceuticals | Jul 21, 2021 | 24 |
| NCT04784728Healthy · United States | 1 | Completed | Scilex Pharmaceuticals | Aug 31, 2019 | 24 |
| NCT04571879Pain, Procedural · Qatar | 3 | UNKNOWN | Hamad Medical | Dec 30, 2023 | 48 |
| NCT04320173Healthy · United States | 1 | Completed | Scilex Pharmaceuticals | Mar 22, 2017 | 47 |
| NCT04319926Healthy · United States | 1 | Completed | Scilex Pharmaceuticals | Sep 9, 2018 | 24 |
| NCT04312750Healthy | 1 | Completed | Scilex Pharmaceuticals | Dec 2015 | 54 |
| NCT04167189Attention Deficit Disorder with Hyperactivity · United States | Early 1 | Completed | PhenoSolve | Mar 30, 2020 | 28 |
| NCT04150536Healthy | 1 | Completed | Scilex Pharmaceuticals | Jan 25, 2016 | 12 |
| NCT04149938Healthy | 1 | Completed | Scilex Pharmaceuticals | Oct 27, 2016 | 54 |
| NCT04144192Healthy | 1 | Completed | Scilex Pharmaceuticals | Jul 24, 2014 | 58 |
| NCT03765697Neuralgia, Postherpetic | 3 | Completed | Grünenthal | Jul 12, 2005 | 259 |
| NCT03745404Neuralgia, Postherpetic | 3 | Completed | Grünenthal | Jun 30, 2004 | 265 |
| NCT03680885Attention Deficit Disorder with Hyperactivity · United States | Early 1 | Completed | PhenoSolve | Mar 30, 2020 | 20 |
| NCT03676725Attention Deficit Disorder with Hyperactivity · United States | Early 1 | Completed | PhenoSolve | Mar 1, 2020 | 90 |
| NCT03663101Chronic Scar Pain · United Kingdom | 2 | Completed | Ipsen | Nov 8, 2019 | 16 |
| NCT03653260Acute Pain · China | 3 | Completed | Lee's Pharmaceutical | Feb 28, 2019 | 288 |
| NCT03354312Periodontitis · Germany | 4 | Completed | chemische-fabrik-kreussler-co-gmbh | Nov 2, 2018 | 94 |
| NCT02749123Back Pain · United States | – | UNKNOWN | j-a-r-laboratories | May 2016 | 100 |
| NCT02452112Herpes Zoster Pain · China | 3 | Completed | Mundipharma | Dec 30, 2015 | 243 |
| NCT02679339Acute-onset Herpes Zoster Pain · Australia | 1 | Terminated | centrexion-therapeutics | Aug 2015 | 1 |
| NCT02066844Hip Fractures · United States | 2 | Completed | cartiva-inc | Aug 2014 | 40 |
| NCT02006173Pain · Taiwan | – | Withdrawn | scivision-biotech-inc | Jul 2015 | 0 |
| NCT01744197Pain · United States | 2 | Completed | Sarah Cannon Research Institute | Feb 2013 | 61 |
| NCT01752322Pain · Austria, Belgium, Brazil and more | 3 | Completed | Grünenthal | Jun 2016 | 444 |
| NCT01602757Healthy · United States | 1 | Completed | ZARS Pharma | Mar 2010 | 12 |
| NCT01545765Healthy Volunteers · United States | 4 | Completed | Galderma Group | May 2012 | 30 |
| NCT01416116Peripheral Nerve Injuries · Belgium, Czechia, Denmark and more | 4 | Completed | Astellas Pharma | Apr 25, 2012 | 122 |
| NCT01360749Agnosia · Spain | 2 | Completed | isdin | Nov 2011 | 42 |
| NCT01329796Endometriosis · Sweden | 2 | Completed | isifer-ab | Jun 2009 | 42 |
| NCT01298310Morton Neuroma · Sweden | Early 1 | Completed | AstraZeneca | May 2012 | 27 |
| NCT01265446Pharyngitis · Germany | 3 | Completed | Novartis | Apr 2011 | 250 |
| NCT01155986Pain · France | 2 | Terminated | Grünenthal | Nov 2012 | 74 |
| NCT01111773Patellar Tendinopathy · United States | 2 | Completed | ZARS Pharma | Mar 2011 | 13 |
| NCT01106989Myofascial Pain Syndromes · United States | 2 | Completed | ZARS Pharma | Dec 2010 | 20 |
| NCT01055444Shoulder Impingement Syndrome · United States | 2 | Completed | ZARS Pharma | Aug 2010 | 20 |
| NCT00991068Carpal Tunnel Syndrome · United States | 2 | Completed | ZARS Pharma | Mar 2010 | 24 |
| NCT00904605Osteoarthritis, Knee · United States | 4 | Terminated | Keenova Therapeutics | Nov 2004 | |
| NCT00904540Acute and Chronic Non-radicular LBP · United States | 4 | Completed | Keenova Therapeutics | Oct 2002 | 131 |
| NCT00904475Chronic Low Back Pain · United States | 4 | Completed | Keenova Therapeutics | Apr 2003 | 102 |
| NCT00904462Osteoarthritis, Knee · United States | 2 | Completed | Keenova Therapeutics | Sep 2005 | 224 |
| NCT00904397Chronic Low Back Pain · United States | 4 | Terminated | Keenova Therapeutics | Nov 2004 | 98 |
| NCT00904202Neuralgia, Postherpetic · United States | 4 | Completed | Keenova Therapeutics | Jun 2003 | 62 |
| NCT00904111Chronic Low Back Pain · United States | 2 | Completed | Keenova Therapeutics | Oct 2005 | 215 |
| NCT00904020Neuralgia, Postherpetic · United States | 4 | Completed | Keenova Therapeutics | Nov 2002 | 107 |
| NCT00903851Diabetes Mellitus · United States | 4 | Completed | Keenova Therapeutics | Jun 2003 | 76 |
| NCT00747669Pain · United States | 4 | Suspended | ZARS Pharma | Apr 2013 | 11 |
| NCT00651313Dysmenorrhea · United States | 2 | Completed | juniper-pharmaceuticals-inc | Jun 2008 | 81 |
| NCT00590590Vulvodynia · United States, Canada | 2 | Completed | lumara-health-inc | Jun 2009 | 105 |
| NCT00589979Osteoarthritis, Knee · United States | 2 | Completed | Keenova Therapeutics | Jun 2008 | 169 |
| NCT00266214Carpal Tunnel Syndrome · United States | 3 | Terminated | Keenova Therapeutics | Jan 2007 | 210 |
| NCT00146185Pain · United States | 3 | Completed | AlgoRx Pharmaceuticals | 504 | |
| NCT00140088Pain, Procedural · United States | 3 | Completed | AlgoRx Pharmaceuticals | 504 | |
| NCT00132405Pain · United States | 2 | Completed | AlgoRx Pharmaceuticals | 260 |
How it is read
Names in the registry
- “Lidocaine”, 8 entries
- “Lidoderm®”, 5 entries
- “Lidocaine topical system 1.8%”, 4 entries
- “Lidoderm”, 4 entries
- “Lidocaine 5% medicated plaster”, 3 entries
Codes read as this program: CNTX2022.
Conditions, from the studies’ own filings
- Pain, 8 studies
- Neuralgia, Postherpetic, 4 studies
- Attention Deficit Disorder with Hyperactivity, 3 studies
- Osteoarthritis, Knee, 3 studies
- Low Back Pain, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.